2019
DOI: 10.1515/med-2019-0087
|View full text |Cite
|
Sign up to set email alerts
|

Use of rituximab in NHL malt type pregnant in I° trimester for two times

Abstract: AbstractAdministration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. Howe ver, several cases of pregnant women being treated with rituximab are reported herein; an exception is often made in cases with grave illness.We describe an excep… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
20
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
6
3

Relationship

8
1

Authors

Journals

citations
Cited by 28 publications
(20 citation statements)
references
References 11 publications
0
20
0
Order By: Relevance
“…One month later, fluorescence in-situ hybridization (FISH) was performed to assess the mutational status of BCL2, BCL6 and MYC genes and showed no genetic rearrangements. Based on clinical and instrumental findings, Stage IE was assigned according to the Ann Arbor staging Lamivudine prophylaxis was administered 4 weeks before chemotherapy according to current guidelines [10][11][12][13].…”
Section: Case Reportmentioning
confidence: 99%
“…One month later, fluorescence in-situ hybridization (FISH) was performed to assess the mutational status of BCL2, BCL6 and MYC genes and showed no genetic rearrangements. Based on clinical and instrumental findings, Stage IE was assigned according to the Ann Arbor staging Lamivudine prophylaxis was administered 4 weeks before chemotherapy according to current guidelines [10][11][12][13].…”
Section: Case Reportmentioning
confidence: 99%
“…The CLL associated with del(11q) or del (17p) among clinical forms with the worst prognosis [3]. Clinical studies have shown that Ibrutinib has been used to treat the clinical form associated with the mutation del(17p), a more favorable response than that obtained with a conventional chemotherapy (rituximab, cyclophosphamide, fludarabine) [4]. This is the first clinical report of an 80-year-old patient with CLL related to del(11q), who presented voluminous solid tissue in the abdominal cavity (23 × 14 × 4 cm) which occupied the whole of the mesentery and the retroperitoneal space by displacing the pancreas anteriorly and the intestinal loops laterally, which prevented adequate nutrition.…”
Section: Introductionmentioning
confidence: 99%
“…Especially in lymphomas, but also in other neoplasms, the mechanisms involving these cells are altered, helping to not amplify neuropathic pain [16][17][18][19][20]. It is evident that the complexity of the pathogenesis of neuropathic pain does not allow unambiguous solutions in these patients who should be mobilized immediately after surgical In our study 51 elderly patients who had undergone a transthoracic biopsy to verify one suspect of mediastinal lymphoma were examined for pain reduction with oral opioids, effect of epidural analgesia and paravertebral block [33][34][35][36].…”
Section: Introductionmentioning
confidence: 99%